ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-OR098

The Impact of the IDEAL Trial on Early Initiation of Dialysis

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Ferguson, Thomas W., Seven Oaks General Hospital, Winnipeg, Manitoba, Canada
  • Garg, Amit X., London Health Sciences Centre, London, Ontario, Canada
  • Sood, Manish M., Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
  • Komenda, Paul, University of Manitoba, Winnipeg, Manitoba, Canada
  • Alam, Ahsan, McGill University Health Centre, Montreal, Quebec, Canada
  • Tangri, Navdeep, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada
  • Rigatto, Claudio, Chronic Disease Innovation Centre, Winnipeg, Manitoba, Canada
  • Naimark, David M., Sunnybrook Health Science Centre, Toronto, Ontario, Canada
  • Beaulieu, Monica C., University of British Columbia, North Vancouver, British Columbia, Canada
  • Manns, Braden J., Foothills Medical Center, Calgary, Alberta, Canada
  • Kim, Joseph, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada

In August 2010, the Initiating Dialysis Early and Late (IDEAL) trial was published and randomized patients with pre-dialysis CKD to planned initiation of dialysis in the eGFR range of 10 to 14 ml/min/1.73m2 (early start) vs. 5 to 7 ml/min/1.73m2 (late start). It concluded that earlier initiation was not associated with improved survival or clinical outcomes. The degree by which this information was disseminated and applied in practice is unknown. We aimed to determine the impact of the IDEAL trial on the proportion of patients who initiate dialysis early (eGFR > 10.5 ml/min/1.73m2).


A segemented regression analysis was performed including all incident adult dialysis patients from the Canadian Organ Replacement Register (CORR) with at least 90 days of nephrologist care before starting dialysis with a recorded eGFR at dialysis initiation.The primary outcome was the change in the proportion of early dialysis starts (eGFR at initiation > 10.5 ml/min/1.73m2). Secondary outcomes included the change in the proportion of acute inpatient dialysis initiations, the proportion of patients who received home dialysis as initial therapy, and the proportion of hemodialysis patients who started dialysis with an arteriovenous (AV) fistula.


Following the IDEAL trial we observed an immediate decline in the proportion of early dialysis starts of 4.49% (95% confidence interval 1.24 to 7.74; p = 0.0080), and there was a significant decrease from the pre-trial annual slope of 2.76% (1.68 to 3.84; p = < 0.001), resulting in an annual decrease of 1.44% (0.84 to 2.16; p < 0.001) in the post-trial period. Acute inpatient dialysis initiations increased immediately following the publication by 2.86% (0.10 – 5.62; p = 0.0440), however there was no sustained change. The proportion of patients who received home dialysis as initial therapy and the proportion who initiated hemodialysis with an AV fistula did not have immediate or sustained differences.


The IDEAL trial had a strong and sustained impact on the timing of dialysis initiation in Canada. These changes were accompanied by no sustained effects on home dialysis as initial therapy, AV fistula construction, or acute inpatient dialysis initiation


  • Government Support - Non-U.S.